Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Sponsor
Ruijin Hospital
Study ID
NCT05923879
Status
Unknown

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a retrospective observational study of the therapeutic mechanism and resistance mechanism of the treatment of Selinexor combined with lenalidomide and rituximab in diffuse large B-cell lymphoma patients. By detecting the immune cells in peripheral blood and tumor tissues of patients before and after treatment, the key immune cell subsets and immune molecules linked to the action and resistance of the treatment of Selinexor combined with lenalidomide and rituximab, so as to provide the basis for the optimization of the treatment or the combination of other immunotherapies.

Key Dates

First listed
Jun 28, 2023
Start date
Jun 30, 2023
Status verified
Jun 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
30 participants (estimated)

Primary Outcome Measure

Tumor tissues collected before treatment and at the point of progression if available for DNA sequencing after quality control. [ Time Frame: 2023/06/30-2025/06/30 ]

Related Studies